San Diego, CA (PRWEB) August 10, 2013
The latest consumer update on information about the progress of lawsuits alleging that women who used the popular contraceptive NuvaRing suffered serious blood-clotting problems was announced today by Resource4thePeople.
The latest news is that NuvaRing lawsuits continue to be filed and efforts by the defendants to dismiss an action in this litigation were rejected by a federal judge.
One of the most recent NuvaRing lawsuits was filed by a California woman who, according to the complaint* she filed in U.S. District Court in New Jersey, attributes a serious blood-clotting problem to her use of the NuvaRing contraceptive.
"This lawsuit is among hundreds of other in which women claim that the manufacturers of the NuvaRing vaginal ring contraceptive has caused them to suffer life-threatening blood-clotting problems," said Resource4thePeople.
"As consumers increasingly inquire about their legal rights in regards to such alleged side effects Resource4thePeople is announcing it will continue to offer free consultations for these consumers through our national network of attorneys over what legal options they may have to seek compensation over these allegations."
The California woman's lawsuit also alleges that the manufacturers of the contraceptive were aware that the NuvaRing put women at greater risk of suffering blood clots but failed to adequately inform consumers and government regulators.
Resource4thePeople also is reporting an important ruling in the multidistrict litigation* of consolidated federal NuvaRing lawsuits in which there are at least 1,217 actions pending, according to the court file.
That litigation is being overseen by a single federal judge in U.S. District Court for the Eastern District of Missouri over the same allegations that blood clots from the NuvaRing caused women to suffer injuries including pulmonary embolism, stroke, deep vein thrombosis (DVT) or sudden death.
"The judge in this huge multidistrict litigation has recently rejected*** a request by one of the defendant companies in the litigation to dismiss a suit filed by a woman who claimed that she suffered deep vein thrombosis and a pulmonary embolism she attributes to the use of the NuvaRing," said Resource4thePeople.
The legal motion to dismiss was filed by Organon USA, a subsidiary of pharmaceutical giant Merck, who are among the defendants, according to the court file.
"It is common for defendants to attempt to have cases dismissed during the progress of multidistrict litigations," said Resource4thePeople. "The fact of the matter is that there are still over 1,200 cases pending before this judge."
Resource4thePeople said the progress of this litigation does not bar other women from filing their own NuvaRing lawsuits alleging serious, life-threatening blood-clotting problems.
"There continues to be an increasing number of consumer inquiries about what legal options there are to seek compensation over such alleged side effects and our national network of experienced attorneys will continue to offer free consultations in such cases."
The cases that have been consolidated before Missouri U.S. District Judge Rodney Sippel involve common allegations that are summed up on the court’s multidistrict litigation web site and include the following language:
“NuvaRing is a prescription contraceptive device used by women throughout the United States. The individual plaintiffs in this matter claim that use of NuvaRing caused them injuries. They have filed suit in several state and federal courts alleging that the manufacturer of NuvaRing failed to adequately warn of the risks associated with the use of the product, and/or that the NuvaRing product is otherwise defective and unreasonably dangerous.”**
The first bellwether trial from the pool of federal lawsuits involving claims that the NuvaRing puts women at higher risk of suffering blood clots than other contraceptives is scheduled to begin in October.
The number of federal NuvaRing allegation lawsuits consolidated before Judge Sippel has climbed to 1,163, according to the latest statistics compiled by the United States Judicial Panel for Multidistrict Litigation.****
In addition, over 200 such state court cases are under the supervision of a judge in New Jersey Superior Court, where another multidistrict litigation***** is underway.
Named as defendants in these litigations are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.
The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.
On Oct. 27, 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.******
Resource4thePeople also notes that NuvaRing has now posted a warning about the increased risks of suffering blood clots on the company’s web site under the heading of “IMPORTANT SAFETY INFORMATION."*******
- Case # 2:2013cv04195, United States District Court for the District of New Jersey
**In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, U.S. District Court, Eastern District of Missouri
*** in re: NuvaRing Products Liability Litigation, No. 08-md-01964-RWS Docket Item #: 1598, Judge Rodney Sippel
*****In Re NuvaRing Litigation, Docket No. BER-L-3081-09, Bergen County, New Jersey Superior Court
******http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf FDA Oct. 27, 2011